All In Biotech

Drug Trial Radar · NCT04275492

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets

Last checked: Nov 19, 2026Latest source record: Mar 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

30

Actual

Start

Jul 24, 2020

Primary completion

Oct 1, 2020

Study completion Dec 1, 2020

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hongguan biological pharmaceutical co.
First posted
Feb 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of In two kinds of fasting and postprandial Chinese healthy subjects with Boehringer represent Ingelheim company production of hydrochloric acid Pramipexole zyban (specification: 0.26 mg/piece, in Pramipexole, commodity name: Siforl ®) as the reference preparation, study a single oral dose of macro crown biological pharmaceutical co., LTD. Production of Pramipexole Dihydrochloride Sustained Release Tablets (specification:The pharmacokinetic parameters of the drug were calculated after the time course of the drug in vivo (0.375mg/ tablet, as measured by pramipexole hydrochloride), and the human relative bioavailability of the two preparations were compared to evaluate their bioequivalence. A secondary purpose To evaluate the safety of fasting and postprandial oral test preparations and reference preparations.

Conditions

  • Parkinson's Disease

Interventions

  • Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)Drug

    Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD

  • Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)Drug

    Siforl® is produced by Boehringer Ingelheim International Gmbh

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: [time range: 72 hours post-dose on Day 1,8]
  2. TmaxTime frame: [time range: 72 hours post-dose on Day 1,8]
  3. AUC(0-inf)Time frame: [time range: 72 hours post-dose on Day 1,8]
  4. AUC(0-72h)Time frame: [time range: 72 hours post-dose on Day 1,8]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital,ZheJiang Univercity

    Hanzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.